GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

GenScript's 2025 ESG Report moves beyond reporting, to demonstrate a system-level execution - structured around five core pillars - governance, workforce, environment, supply chain, and community - ...

Jefferies analyst Chris Lui maintained a Buy rating on Genscript Biotech (GNNSF – Research Report) on December 21 and set a price target of HK$30.00. The company’s shares closed last Tuesday at $2.65.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...

PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...

As of December 31, 2023, 88,700 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, ...